Benazepril Hydrochloride And Hydrochlorothiazide
NDC Package 15330-159-01

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

This product is EXCLUDED from the official NDC directory because the listing data was discontinued by the firm.

Benazepril Hydrochloride And Hydrochlorothiazide is a . Marketed by Mylan Pharmaceuticals Inc., this product is identified by NDC 15330-159 and is authorized under FDA application ANDA076612.

Identification & Billing

NDC Package Code
15330-159-01
Package Description
100 TABLET in 1 BOTTLE
Product Code
15330-159
11-Digit Billing Format
15330015901

Clinical Specifications

Proprietary Name
Benazepril Hydrochloride And Hydrochlorothiazide
Dosage Form
-

Regulatory & Marketing

Labeler Name
Mylan Pharmaceuticals Inc.
FDA Application #
ANDA076612
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
11-01-2015
End Marketing Date
11-30-2015
Listing Expiration
11-30-2015
Exclude Flag
D
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 15330-159-01 identifies a specific commercial package of 100 tablet in 1 bottle of Benazepril Hydrochloride And Hydrochlorothiazide, labeled by Mylan Pharmaceuticals Inc.. This is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Mylan Pharmaceuticals Inc. on November 01, 2015. The current certification is valid through November 30, 2015.

How is this Mylan Pharmaceuticals Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 15330015901. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
15330-159-01
11-Digit CMS (5-4-2)
15330-0159-01

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.